Dr. Douglas Evans on Neadjuvant Therapy for Pancreas Cancer

Douglas B. Evans, MD, FACS
Published: Tuesday, Apr 26, 2016



Douglas B. Evans, MD, FACS, Chair, Professor, Donald C. Ausman Family Foundation Professor of Surgery, Medical College of Wisconsin, discusses how to appropriately sequence therapies for pancreatic cancer.

A combination of chemotherapy, surgery, and radiation has been shown to be better than surgery alone, says Evans. However, it is unclear in which sequence to deliver these treatments. This is especially challenging because much of the pancreatic cancer patient population is older, has medical comorbidities, and variable social support, says Evans.

Evans has been interested in neadjuvant treatment sequencing for many years, and now that there are improved systemic therapies, there is more interest in this approach, he says.



Douglas B. Evans, MD, FACS, Chair, Professor, Donald C. Ausman Family Foundation Professor of Surgery, Medical College of Wisconsin, discusses how to appropriately sequence therapies for pancreatic cancer.

A combination of chemotherapy, surgery, and radiation has been shown to be better than surgery alone, says Evans. However, it is unclear in which sequence to deliver these treatments. This is especially challenging because much of the pancreatic cancer patient population is older, has medical comorbidities, and variable social support, says Evans.

Evans has been interested in neadjuvant treatment sequencing for many years, and now that there are improved systemic therapies, there is more interest in this approach, he says.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Integrating Novel Targeted Treatment Strategies to Advance Pancreatic Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x